Paper published in a journal (Scientific congresses and symposiums)
In Vivo Preclinical Molecular Imaging: From the Laboratory Bench to the Patient.
Plenevaux, Alain
2016In Pharmaceuticals, 9 (4), p. 73
Peer Reviewed verified by ORBi
 

Files


Full Text
pharmaceuticals-09-00073 (1)_JFP2016.pdf
Publisher postprint (5.48 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Preclinical molecular imaging plays a key role in the study of diseases and the development, evaluation, andvalidation of novel treatment and diagnostic techniques. The actual aim is to facilitate the translation of innovative therapies and diagnostic agents into patients by providing in vivo proof-of-principle data in animal models of diseases and accordingly match some of the legal requirements before human clinical trials. The real power of preclinical imaging stems from the fact that in vivo data are non-invasively collected, thus making longitudinal studies possible. The evolution of the disease or the actual impact of innovative treatments can be evaluated in the same animal over a long period of time. The major modalities used in preclinical molecular imaging (all present in our laboratory) are the positron emission tomography (microPET), the X-ray tomodensitometry (microCT) and the magnetic resonance imaging (microMRI). The GIGA-CRC In vivo Imaging at ULg is a multidisciplinary laboratory which relies on a medical cyclotron for radioisotope productions, a radiochemistry unit for the development of new radiopharmaceuticals and process automation, a GMP unit for radiopharmaceutical productions, a preclinical imaging unit and a clinical imagingplatform (with MRI, PET, EEG, TMS, . . . ). All expertise and qualified staff are present on site. Our laboratory has all necessary permission and approval for radiopharmaceutical productions and human clinical trials. During this presentation, we will take as an example the development of the first SV2A radioligand [18F]UCB-H (a-b) to illustrate how we can bring new ideas from the laboratory bench to the patient (Bretin, F., et al. Eur. J. Nucl. Med. Mol. Imaging Res. 2013, 3, 35; Warnock, G., et al. J. Nucl. Med. 2014, 55, 1336–1341).
Research center :
GIGA CRC (Cyclotron Research Center) In vivo Imaging-Aging & Memory - ULiège
Disciplines :
Radiology, nuclear medicine & imaging
Author, co-author :
Plenevaux, Alain  ;  Université de Liège > Département de chimie (sciences) > Département de chimie (sciences)
Language :
English
Title :
In Vivo Preclinical Molecular Imaging: From the Laboratory Bench to the Patient.
Publication date :
18 November 2016
Event name :
JFB2016: 30ième Journées Franco-Belges de Pharmacochimie
Event organizer :
Sylvain Routier
Event place :
Amboise, France
Event date :
25-27 Mai 2016
By request :
Yes
Audience :
International
Journal title :
Pharmaceuticals
eISSN :
1424-8247
Publisher :
Molecular Diversity Preservation International (MDPI), Basel, Switzerland
Special issue title :
Meeting Report "30ième Journées Franco-Belges de Pharmacochimie"
Volume :
9
Issue :
4
Pages :
73
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
Available on ORBi :
since 04 January 2017

Statistics


Number of views
60 (9 by ULiège)
Number of downloads
2 (2 by ULiège)

Scopus citations®
 
0
Scopus citations®
without self-citations
0
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi